Aligos Therapeutics, Inc. (ALGS) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.18
↓-94% vs avg
5yr avg: 20.00
30Y Low1.7·High107.4
ROE
↓
-196.9%
-18% vs avg
5yr avg: -166.4%
30Y Low-416%·High-63%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ALGS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Aligos Therapeutics, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $39M | $92M | $250M | $413M | $1.0B | $11.8B | $23.6B | — | — |
| Enterprise Value | $26M | $79M | $221M | $288M | $948M | $11.7B | $23.4B | — | — |
| P/E Ratio → | -2.60 | — | — | — | — | — | — | — | — |
| P/S Ratio | 18.03 | 42.14 | 63.27 | 26.59 | 73.13 | 2713.26 | — | — | — |
| P/B Ratio | 1.18 | 1.72 | — | 4.48 | 9.79 | 64.02 | 107.37 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ALGS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 36.17 | 56.01 | 18.57 | 68.18 | 2673.72 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
ALGS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Aligos Therapeutics, Inc. earns an operating margin of -4024.9%. Operating margins have compressed from -567.5% to -4024.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -196.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 57.5% | 57.5% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| Operating Margin | -4024.9% | -4024.9% | -2259.9% | -567.5% | -701.7% | -2943.8% | — | — | — |
| Net Profit Margin | -1106.7% | -1106.7% | -3326.0% | -564.6% | -690.6% | -2944.1% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -196.9% | -196.9% | -415.8% | -89.5% | -66.6% | -63.4% | -139.9% | — | — |
| ROA | -30.5% | -30.5% | -118.4% | -58.8% | -50.3% | -51.3% | -52.7% | -41.1% | -12.9% |
| ROIC | -163.0% | -163.0% | — | -5005.3% | -308.2% | -768.9% | -579.4% | — | — |
| ROCE | -152.1% | -152.1% | -101.3% | -73.1% | -63.0% | -59.5% | -53.2% | -46.4% | -13.6% |
ALGS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $18M exceeds total debt of $5M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.10 | 0.10 | — | 0.12 | 0.12 | 0.08 | 0.06 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.24 | — | -1.35 | -0.66 | -0.93 | -0.94 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -10.28 | — | — |
Net cash position: cash ($18M) exceeds total debt ($5M)
ALGS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Aligos Therapeutics, Inc.'s current ratio of 3.90x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.90x to 3.90x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.90 | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Quick Ratio | 3.90 | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 | 8.26 | 8.70 | 12.33 |
| Cash Ratio | 3.67 | 3.67 | 2.62 | 5.68 | 3.80 | 4.90 | 8.04 | 8.52 | 12.13 |
| Asset Turnover | — | 0.02 | 0.06 | 0.10 | 0.09 | 0.02 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — |
ALGS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Aligos Therapeutics, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $10M | $6M | $25M | $43M | $40M | $34M | $22M | $21M |
Peer Comparison
Compare ALGS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ALGSYou | $39M | -2.6 | — | — | 57.5% | -4024.9% | -196.9% | -163.0% | — |
 ARWR | $11B | -6486.9 | 91.8 | 70.6 | 97.1% | 11.9% | -0.5% | 9.3% | 3.0 |
 HALO | $8B | 25.9 | 8.5 | 12.1 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 GILD | $170B | 358.7 | 42.1 | 16.5 | 78.3% | 5.8% | 2.3% | 3.2% | 6.0 |
 VRTX | $109B | 27.9 | 21.7 | 34.1 | 85.0% | 39.4% | 22.5% | 23.0% | 0.8 |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 MDGL | $12B | -42.0 | — | — | 94.1% | -31.3% | -42.5% | -29.4% | — |
 AKRO | $4B | -14.6 | — | — | — | — | -39.2% | -55.3% | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See ALGS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ALGS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ALGS vs ARWR
Side-by-side business, growth, and profitability comparison vs Arrowhead Pharmaceuticals, Inc..
Start ComparisonALGS — Frequently Asked Questions
Quick answers to the most common questions about buying ALGS stock.
What is Aligos Therapeutics, Inc.'s P/E ratio?
Aligos Therapeutics, Inc.'s current P/E ratio is -2.6x. This places it at the 50th percentile of its historical range.
What is Aligos Therapeutics, Inc.'s ROE?
Aligos Therapeutics, Inc.'s return on equity (ROE) is -196.9%. The historical average is -162.0%.
Is ALGS stock overvalued?
Based on historical data, Aligos Therapeutics, Inc. is trading at a P/E of -2.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Aligos Therapeutics, Inc.'s profit margins?
Aligos Therapeutics, Inc. has 57.5% gross margin and -4024.9% operating margin.